登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由江苏省人民医院(南医大一附院)牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07394387,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 70 岁;性别:仅女性
登记记录的入选字段
Histologically confirmed invasive breast cancer, classified as Stage II-III triple-negative breast cancer (TNBC) according to the 8th edition AJCC TNM staging.
入选标准第 2 条
Normal thyroid function (T3, T4, FT3, FT4, TSH).
入选标准第 20 条
Major surgery within 4 weeks prior to study initiation or anticipated need for major surgery during the study.
排除标准第 6 条
ECOG performance status of 0 or 1.
入选标准第 5 条
Hemoglobin ≥90 g/L
入选标准第 7 条
Platelet count ≥100×10\^9/L
入选标准第 9 条
Absolute neutrophil count ≥1.5×10\^9/L
入选标准第 10 条
AST and ALT ≤3× upper limit of normal (ULN)
入选标准第 11 条
Total bilirubin ≤1.5× ULN
入选标准第 12 条
Serum creatinine ≤1.5× ULN
入选标准第 13 条
At least one measurable lesion as per RECIST v1.1 criteria.
入选标准第 3 条
Concurrent other malignancies or history of other malignancies within the past 5 years (except adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix).
排除标准第 4 条
HIV positive
排除标准第 12 条
Active hepatitis B (HBV-DNA > 10\^3 IU/mL)
排除标准第 14 条
Active hepatitis C (HCV antibody positive with detectable HCV-RNA)
排除标准第 15 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07394387,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Female patients aged ≥18 and ≤70 years. Histologically confirmed invasive breast cancer, classified as Stage II-III triple-negative breast cancer (TNBC) according to the 8th edition AJCC TNM staging. At least one measurable lesion as per RECIST v1.1 criteria. No prior chemotherapy, immunotherapy, endocrine therapy, radical surgery, or radiotherapy for breast cancer. ECOG performance status of 0 or 1. Adequate organ function, defined as: Hemoglobin ≥90 g/L White blood cell count ≥3.5×10\^9/L Platelet count ≥100×10\^9/L Absolute neutrophil count ≥1.5×10\^9/L AST and ALT ≤3× upper limit of normal (ULN) Total bilirubin ≤1.5× ULN Serum creatinine ≤1.5× ULN No evidence of pneumonia on chest CT Adequate cardiac function, defined as: No myocardial ischemia on ECG NYHA class I LVEF ≥55% on echocardiogram Normal cardiac markers (cTnI and BNP) Normal thyroid function (T3, T4, FT3, FT4, TSH). Willing and able to provide written informed consent.排除标准:Exclusion Criteria:
Male or inflammatory breast cancer. Metastatic (Stage IV) breast cancer. History of active autoimmune or inflammatory diseases requiring systemic treatment within the past 2 years (e.g., systemic lupus erythematosus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Hashimoto's thyroiditis). Exceptions: type I diabetes, hypothyroidism controlled with hormone replacement therapy, or skin disorders not requiring systemic treatment (e.g., vitiligo, psoriasis). Concurrent other malignancies or history of other malignancies within the past 5 years (except adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix). Any other serious non-malignant disease that may compromise compliance or place the patient at risk. Major surgery within 4 weeks prior to study initiation or anticipated need for major surgery during the study. Prior radiotherapy, chemotherapy, targeted therapy, endocrine therapy, or major surgery for breast cancer. Known hypersensitivity to any component of the study drugs. Poorly controlled cardiac disease (e.g., NYHA class II+ heart failure, unstable angina, myocardial infarction within the past year, or clinically significant arrhythmias requiring intervention). History of interstitial lung disease (ILD), current ILD, or suspected ILD on imaging during screening. Active infections, including: HIV positive Active tuberculosis Active hepatitis B (HBV-DNA > 10\^3 IU/mL) Active hepatitis C (HCV antibody positive with detectable HCV-RNA) Active autoimmune disease requiring systemic treatment. Dementia, significant intellectual impairment, or any psychiatric condition that impairs understanding of the informed consent. Unhealed wounds, ulcers, or fractures within 4 weeks prior to signing consent; or any history of clinically significant bleeding or bleeding tendency. Any other condition deemed by the investigator to be unsuitable for trial participation.
引自 ClinicalTrials.gov, NCT07394387, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07394387,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。